iRhythm Holdings, Inc. (IRTC)
| Market Cap | 3.74B -16.5% |
| Revenue (ttm) | 787.85M +27.4% |
| Net Income | -27.78M |
| EPS | -0.86 |
| Shares Out | 32.86M |
| PE Ratio | n/a |
| Forward PE | 408.90 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 320,374 |
| Open | 115.61 |
| Previous Close | 115.61 |
| Day's Range | 113.62 - 117.41 |
| 52-Week Range | 108.81 - 212.00 |
| Beta | 1.33 |
| Analysts | Strong Buy |
| Price Target | 180.93 (+58.85%) |
| Earnings Date | Apr 30, 2026 |
About IRTC
iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that ... [Read more]
Financial Performance
In 2025, iRhythm Holdings's revenue was $747.14 million, an increase of 26.24% compared to the previous year's $591.84 million. Losses were -$44.55 million, -60.67% less than in 2024.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for IRTC stock is "Strong Buy." The 12-month stock price target is $180.93, which is an increase of 58.85% from the latest price.
News
iRhythm Holdings Transcript: AGM 2026
The meeting covered director elections, approval of the 2026 Equity Incentive Plan, amendments to governance documents, auditor ratification, and executive compensation. All proposals passed, and stockholder questions will be addressed post-meeting.
iRhythm Holdings to Participate in Upcoming Investor Conferences
SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict dise...
iRhythm price target lowered to $180 from $225 at BofA
BofA lowered the firm’s price target on iRhythm (IRTC) to $180 from $225 and keeps a Buy rating on the shares. After having hosted 34 medtech companies last week in…
iRhythm Technologies Touts Medicare Win, Zio Growth and AI-Driven Margin Gains
iRhythm Technologies NASDAQ: IRTC executives said the company is seeing continued business momentum after a favorable Medicare coverage update, a stronger-than-expected first quarter and progress on s...
iRhythm Holdings Transcript: Bank of America Global Healthcare Conference 2026
LCD updates expanded patient access and Q1 delivered strong revenue and margin growth, led by Zio Monitor and innovative channels. AI-driven efficiencies and new product launches are expected to drive further margin gains, while international and innovative channel expansion remain key growth areas.
iRhythm price target raised to $157 from $155 at Citi
Citi raised the firm’s price target on iRhythm (IRTC) to $157 from $155 and keeps a Buy rating on the shares.
iRhythm price target raised to $174 from $170 at Truist
Truist raised the firm’s price target on iRhythm (IRTC) to $174 from $170 and keeps a Buy rating on the shares. The company delivered another strong revenue and EBITDA beat…
iRhythm price target raised to $175 from $166 at Baird
Baird raised the firm’s price target on iRhythm (IRTC) to $175 from $166 and keeps an Outperform rating on the shares. The firm updated its model following beat and raise…
iRhythm price target lowered to $175 from $215 at JPMorgan
JPMorgan lowered the firm’s price target on iRhythm (IRTC) to $175 from $215 and keeps an Overweight rating on the shares.
iRhythm price target lowered to $185 from $225 at Oppenheimer
Oppenheimer lowered the firm’s price target on iRhythm (IRTC) to $185 from $225 and keeps an Outperform rating on the shares following quarterly results. The firm notes there were no…
iRhythm price target lowered to $160 from $170 at Evercore ISI
Evercore ISI lowered the firm’s price target on iRhythm (IRTC) to $160 from $170 and keeps an Outperform rating on the shares.
iRhythm price target raised to $255 from $254 at Needham
Needham raised the firm’s price target on iRhythm (IRTC) to $255 from $254 and keeps a Buy rating on the shares after its Q1 earnings beat. The company continues to…
iRhythm price target lowered to $180 from $198 at Canaccord
Canaccord lowered the firm’s price target on iRhythm (IRTC) to $180 from $198 and keeps a Buy rating on the shares. The firm said they delivered a solid Q1 with…
iRhythm Holdings Earnings Call Transcript: Q1 2026
Q1 2026 saw 25.7% revenue growth, margin expansion, and improved profitability, driven by strong volume across core and emerging channels. Guidance for 2026 was raised, with continued investment in AI, workflow integration, and international growth.
iRhythm Holdings Earnings release: Q1 2026
iRhythm Holdings released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
iRhythm Holdings Slides: Q1 2026
iRhythm Holdings has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 30, 2026.
iRhythm Holdings Quarterly report: Q1 2026
iRhythm Holdings has published its Q1 2026 quarterly earnings report on April 30, 2026.
iRhythm sees FY26 revenue $875M-$885M, consensus $876.16M
For the full year 2026, iRhythm (IRTC) expects revenue between $875 million and $885 million and adjusted EBITDA margin between 12% and 13%, reflecting continued volume-led growth, gross margin expans...
iRhythm Holdings Announces First Quarter 2026 Financial Results
SAN FRANCISCO, April 30, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent d...
iRhythm Holdings to Present at the Bank of America Securities 2026 Health Care Conference
SAN FRANCISCO, April 28, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict di...
New Data Presented at HRS 2026 Show Short-Term Holter Monitoring Misses a Large Proportion of AF Recurrence Post-Ablation and Clinically Significant Arrhythmias in Pregnancy
Real-world data presented at HRS 2026 add to the body of evidence supporting a shift away from short-duration Holter monitoring toward up to 14 days of continuous, uninterrupted monitoring with Zio ® ...
iRhythm Holdings Proxy statement: Proxy filing
iRhythm Holdings filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
iRhythm Holdings Proxy statement: Proxy filing
iRhythm Holdings filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
iRhythm Holdings to Report First Quarter 2026 Financial Results on April 30, 2026
SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict di...
iRhythm price target lowered to $170 from $200 at Truist
Truist analyst Richard Newitter lowered the firm’s price target on iRhythm (IRTC) to $170 from $200 and keeps a Buy rating on the shares as part of a broader research…